COVID-19 inpatients with psychiatric disorders: Real-world clinical recommendations from an expert team in consultation-liaison psychiatry
- 1 June 2020
- journal article
- research article
- Published by Elsevier BV in Journal of Affective Disorders
- Vol. 274, 1062-1067
- https://doi.org/10.1016/j.jad.2020.05.149
Abstract
No abstract availableFunding Information
- Abbott (PI19/00672)
- Allergan
- Angelini
- Bristol-Myers Squibb
- Dainippon Sumitomo Pharma
- Gedeon Richter
- Pfizer
- Roche
- Shire
- Sunovion
- CIBERSAM
- Stanley Medical Research Institute
- Instituto de Salud Carlos IIISubdirección General de Evaluación y Fomento de la investigación
- Spanish Ministry of Science, Innovation and Universities (JR19/00025)
This publication has 18 references indexed in Scilit:
- Patients with mental health disorders in the COVID-19 epidemicThe Lancet Psychiatry, 2020
- The neuroinvasive potential of SARS‐CoV2 may play a role in the respiratory failure of COVID‐19 patientsJournal of Medical Virology, 2020
- Online mental health services in China during the COVID-19 outbreakThe Lancet Psychiatry, 2020
- Mental health services for older adults in China during the COVID-19 outbreakThe Lancet Psychiatry, 2020
- #IAmNotDangerous and the politics of stigmaThe Lancet Psychiatry, 2019
- Mental health-related stigma in health care and mental health-care settingsThe Lancet Psychiatry, 2014
- QTc Interval Prolongation and Torsade de Pointes Associated with Second-Generation Antipsychotics and Antidepressants: A Comprehensive ReviewCNS Drugs, 2014
- QTc Prolongation with AntipsychoticsJournal of Psychiatric Practice, 2014
- Comorbidity of mental and physical diseases: a main challenge for medicine of the 21st century.Shanghai Archives of Psychiatry, 2013
- Risk of pneumonia and pneumococcal disease in people with severe mental illness: English record linkage studiesThorax, 2012